ArticleTrends in molecular medicine2022
Transplantation of neural progenitor cells into the human CNS.
Article in Trends in molecular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 12 citations in OpenAlex.
- Therapeutic frontiers in ALS: iPSC-based drug discovery, cell therapy, and gene therapy-Advances through 2026.Regenerative therapy · 2026Review
- Real-Time Feedback Strategically Regulates Optoelectronics for Customized Optogenetic Spinal Cord Regeneration.Exploration (Beijing, China) · 2026Article
- Functional recovery induced by KCC2-enabled relay pathways in completely injured spinal cords in adult rats.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Traumatic Brain Injury: Novel Experimental Approaches and Treatment Possibilities.Life (Basel, Switzerland) · 2025Review
- Cell therapy for neurological disorders.Nature medicine · 2024Review
- Regenerative medicine strategies for chronic complete spinal cord injury.Neural regeneration research · 2024Review
- Human-induced pluripotent stem cell-derived neural stem/progenitor cell ex vivo gene therapy with synaptic organizer CPTX for spinal cord injury.Stem cell reports · 2024Article
- Biohybrid neural interfaces: improving the biological integration of neural implants.Chemical communications (Cambridge, England) · 2023Review
- In Vitro Models of Amyotrophic Lateral Sclerosis.Cellular and molecular neurobiology · 2023Review
- Human iPSC-derived neural progenitor cells secreting GDNF provide protection in rodent models of ALS and retinal degeneration.Stem cell reports · 2023Article
- Article
- Neuroprotective Effects of Genome-Edited Human iPS Cell-Derived Neural Stem/Progenitor Cells on Traumatic Brain Injury.Stem cells (Dayton, Ohio) · 2023Article
- A review of regenerative therapy for spinal cord injury using human iPS cells.North American Spine Society journal · 2023Article
Corrections and comments
- Comment on
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of regenerative medicine for spinal cord injury (SCI) and intractable diseases of the nervous system using neural progenitor cells (NPCs) has shown great promise, and several clinical trials have begun. In addition, ex vivo gene therapy using genetically engineered NPCs was recently initiated in the clinical setting by Baloh et al., putatively showing enhanced therapeutic effects. Thus, the era of next-generation NPC transplantation therapy is beginning to dawn.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.